SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-219681
Filing Date
2021-07-20
Accepted
2021-07-20 16:30:52
Documents
12
Period of Report
2021-07-16
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d178946d8k.htm   iXBRL 8-K 20858
  Complete submission text file 0001193125-21-219681.txt   141913

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA cdtx-20210716.xsd EX-101.SCH 2873
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE cdtx-20210716_lab.xml EX-101.LAB 18138
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cdtx-20210716_pre.xml EX-101.PRE 11395
5 EXTRACTED XBRL INSTANCE DOCUMENT d178946d8k_htm.xml XML 3363
Mailing Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121
Business Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121 858-752-6170
Cidara Therapeutics, Inc. (Filer) CIK: 0001610618 (see all company filings)

IRS No.: 461537286 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36912 | Film No.: 211101474
SIC: 2836 Biological Products, (No Diagnostic Substances)